In a previous phase II randomized controlled clinical study, Tivantinib, a highly selective c-Met inhibitor, improved median time to progression and OS time in patients with Met-high advanced HCC compared with placebo (Santoro et al., 2013). The gene discussed is MET; the disease is hepatocellular carcinoma.